Cell therapy

Sickle cells
#Beam Therapeutics #Cell therapy #Phase II trial #Sickle cell disorder (SCD)

Trial results support US biologics license application for risto-cel

Beam Therapeutics has shared positive topline results from the BEACON Phase I/II study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).   Risto-cel is an investigational one-time, autologous cell therapy with a potentially differentiated profile for the treatment of SCD. Read More

#News #Trending News

CAR-T therapy
#Allogene Therapeutics #Autoimmune disease #CAR-T #Cell therapy #Phase I trial

First clinical data for allogeneic CAR-T in autoimmune disease

Allogene Therapeutics has reported preliminary safety, efficacy and translational data from the ongoing Phase I RESOLUTION study evaluating ALLO-329, an investigational, off-the-shelf allogeneic CAR-T product designed specifically for autoimmune disease.   The data were presented at the American College of Rheumatology (ACR) Convergence in Orlando, Florida. … Read More

#Editor's Choice #News

#Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Upcoming advances and challenges in cell & gene therapies webinar

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

#Cell and gene therapy #Cell therapy #Drug discovery #Webinar

Webinar: Advances and challenges in cell & gene therapies

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

CAR-T in multiple myeloma
#CAR-T #Caribou Biosciences #Cell therapy #Haematology #Oncology

Caribou Biosciences cancels allogeneic CAR-T programmes

Caribou Biosciences has announced that it is discontinuing its two allogeneic CAR-T cell therapy programmes due to financing constraints.  It will discontinue development of vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. … Read More

#Cancer Research #News

#Cell and gene therapy #Cell therapy #Drug discovery #Gene therapy #Webinar

Have you registered for our CGT webinar?

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Generate Biomedicines #Oncology #Ovarian cancer

First human trials in ovarian cancer for ‘armoured’ CAR-T therapy

Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy.  The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours.  … Read More

#Cancer Research #News #Trending News

DDW CGT Guide
#Cell and gene therapy #Cell therapy #Gene therapy #Guide

Guide: The latest breakthroughs in cell & gene therapies

Despite their challenging nature, cell & gene therapies (CGTs) are becoming ever more successful and accessible one-time treatments for haematological malignancies and genetic diseases, while researchers have recently made significant strides forward in their use to treat other cancers.

#DDW eBooks #DDW Guides

Cell and gene therapy
#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy

Advances and challenges in cell and gene therapies

Hosted by Drug Discovery World and supported by Bio-Techne, this webinar explores the advances and challenges taking place within the cell and gene therapy field. Hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo Therapeutics. Throughout the… Read More

Webinar date:
Sponsored by Bio-Techne
#Featured Webinars

CAR-T cell therapy
#Bristol Myers Squibb #CAR-T #Cell therapy #Clinical trials #Novartis

Novartis and BMS pause CAR-T trials due to safety concerns

Novartis and Bristol Myers Squibb (BMS) have both paused clinical trials of CAR-T cell therapies for lupus and other autoimmune diseases due to concerning safety findings.  Novartis has placed holds on trials of rapcabtagene autoleucel (rap-cel), stopping screening, randomisation, and treatment administration in trials in lupus, myasthenia… Read More

#News #Trending News

CAR-T in multiple myeloma
#CAR-T #Cell therapy #Clinical trial #HaemaLogiX #Oncology

KOALA trial launched to assess CAR-T for myeloma

The first patient has been dosed with PMCC-COE-KMA, an investigational CAR T-cell therapy being developed by Peter MacCallum Cancer Centre’s Centre of Excellence in Cellular Immunotherapy (CoE) and licensed by Australian biotechnology company HaemaLogiX.  The KOALA trial will evaluate the safety and efficacy of PMCC-COE-KMA in patients… Read More

#Cancer Research #News

Map of China
#CAR-T #Cell therapy #China #Oncology #Solid tumours

When the world’s first solid-tumour CAR-T gets approved in China

In June 2026, China’s National Medical Products Administration cleared satricabtagene autoleucel (satri-cel), CARsgen’s Claudin18.2 CAR-T, for advanced gastric cancer. It became the world’s first CAR-T cell therapy approved for a solid tumour. The science is genuinely impressive. But the geography is the story. Satri-cel is not a Chinese… Read More

#Exclusive Content #Opinion #Regulatory

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Oncology #Pancreatic cancer #The University of Texas at Austin

Research uncovers driver of CAR-T resistance in solid tumours

Pancreatic tumours can resist immunotherapy by recruiting nearby immune cells, according to new research, which has revealed a potential new strategy for overcoming resistance in cell therapies.  CAR T-cell therapy has transformed treatment for several blood cancers but has repeatedly stalled against solid tumours such as pancreatic… Read More

#Cancer Research #Editor's Choice #News